Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 9Colorectal Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Neoplasm Metastasis 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 7Oxaliplatin 5Cisplatin 4tremelimumab 3durvalumab 3Radiotherapy 3Paclitaxel 3Leucovorin 3Surgical Procedures, Operative 2Radiation 2Docetaxel 2Cetuximab 2Carboplatin 2Capecitabine 2zanidatamab 1trastuzumab deruxtecan 1rucaparib 1oblimersen 1monalizumab 1cabozantinib 1benzamide 1Trastuzumab 1Taxes 1Ramucirumab 1Nivolumab 1Neoadjuvant Therapy 1Microarray Analysis 1Metabolic Networks and Pathways 1LY2940680 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma Of Esophagus × Ado-Trastuzumab Emtansine × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡